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Abstract: The aim of the study was to explore the possibility that propolis can control diabetes 
mellitus and prevent diabetic osteopathy in rats. The study compared 60 streptozotocin (STZ)-
induced diabetic rats, with ten nondiabetic rats used as a negative control. The experimental 
design comprised seven groups (n = 10 rats per group): (1) nondiabetic, used as a negative control; 
(2) nontreated, used as a positive control; (3) treated with insulin alone; (4) treated with a single 
dose of propolis alone; (5) treated with a double dose of propolis; (6) treated with insulin and a 
single dose of propolis; and (7) treated with insulin and a double dose of propolis. After 6 weeks 
of treatment, the rats were sacrificed. Ratios of femur ash to femur weight and of femur weight to 
body weight (FW/BW) were calculated and calcium (Ca), phosphorus (P), and magnesium (Mg) 
concentrations in femur ash were estimated and analyzed. Fasting blood glucose (FBG), plasma 
insulin and glucagon, serum thiobarbituric acid reactive substances (TBARS), plasma parathyroid 
hormone (PTH), and calcitonin levels were also estimated and analyzed. There was significant 
reduction in FBG in all diabetic treated rats. Similarly, higher plasma insulin levels were observed 
in diabetic rats treated with propolis and insulin than in nontreated diabetic rats, although plasma 
insulin was not comparatively higher in diabetic rats treated with insulin alone. Serum TBARS 
was significantly lower in the propolis treated rats than the diabetic nontreated rats. No differences 
in PTH and calcitonin levels were observed among treatment groups. The FW/BW ratio was 
significantly higher in diabetic treated groups than in control groups. Furthermore, diabetic rats 
treated with propolis and insulin had significantly higher Ca, P, and Mg concentrations in femoral 
ash than nontreated diabetic rats and diabetic rats treated with insulin alone. In conclusion, propolis 
has a remarkable effect on glucose homeostasis and bone mineralization.
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Introduction
Diabetes mellitus (DM) is the most common serious metabolic disorder in humans. It is 
characterized by hyperglycemia as a result of insulin shortage or insufficient insulin 
action, or both.1 Insulinopenia, which occurs in type 1 diabetes (T1DM), is associated 
with decreased bone density and a state of low bone turnover.2,3
Hyperglycemia is an important factor responsible for the intense oxidative stress in 
diabetes, and the toxicity induced by glucose autoxidation is likely to be one of the 
important sources of reactive oxygen species.4 Additionally, lipid peroxidation plays an 
important role in the production of free radicals and oxidative stress in   diabetes.5 Several 
intra- and extracellular antioxidant defense mechanisms   counteract the destructive 
effects of free radicals by attenuating or omitting their activities.6 However, in DM 
the oxidative stress exceeds the body’s antioxidant defense   mechanisms. Although 
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oxidative stress and free radicals have been reported to play a 
significant role in diabetic complications7 and treatment with 
antioxidants has been reported to reduce these complications,8 
few studies have focused on diabetic osteopathy.
Recent studies have shown that propolis has   hypoglycemic, 
hypolipidemic, and antioxidant activity,9 which can be used 
to prevent or delay the appearance of diabetic complications. 
Its hypoglycemic activity has been attributed to inhibition of 
intestinal maltase activity, preventing rise of blood   glucose 
following carbohydrate intake. Propolis has also been 
reported to enhance the antioxidant defense system10 and to 
protect pancreatic tissue.9
In view of recent claims that propolis can cure streptozo-
tocin (STZ)-induced DM,9 the authors extend their studies to 
investigate the effect of propolis on the control of diabetes 
and the prevention of diabetic osteopathy in STZ-induced 
diabetic rats.
Material and methods
Adult male albino rats (obtained from the animal house at the 
University of Dammam, Dammam, Saudi Arabia) weighing 
150–300 g were housed at a constant temperature (22°C) under 
a 12-hour light-dark cycle and were provided with standard 
rat food and water ad libitum. The University of Dammam 
ethics committee approved the protocol. The study compared 
60 streptozotocin (STZ)-induced diabetic rats, with ten nondia-
betic rats used as a negative control. The experimental design 
comprised seven groups (n = 10 rats per group): (1) nondia-
betic, used as a negative control (GI); (2) nontreated, used as a 
positive control (GII-1); (3) treated with insulin alone (GII-2); 
(4) treated with a single dose of propolis (0.3 g/kg) alone 
(GII-3); (5) treated with a double dose of propolis (0.6 g/kg) 
(GII-4); (6) treated with insulin and a single dose of propolis 
(0.3 g/kg) (GII-5); and (7) treated with insulin and a double 
dose of propolis (0.6 g/kg) (GII-6).
T1DM was induced in the experimental rats11 by admin-
istering a single-dose intraperitoneal (IP) injection of STZ 
(60 mg/kg) (Sigma-Aldrich Co, St Louis, MO), dissolved 
in distilled water. Three days after the STZ injection, urine 
strips (Medi-Test Combi 10; Macherey-Nagel GmbH & 
Co, Düren, Germany) were used to detect glycosuria in rats 
(a dark-green color indicated blood glucose $ 500 mg/dL).12 
These 60 STZ-induced diabetic rats were randomly divided 
into the six subgroups, GII-1 to GII-6, in the study.
Treatment of all rats included in the study started daily at 
7 am and continued for 6 weeks. Both the negative control 
and positive control groups (GI and GII-1, respectively) 
received a daily IP injection with normal saline and received 
1 mL of water through a rat feeding needle (Kent Scientific 
  Corporation, Torrington, CT).13 Groups GII-2, GII-5, and 
GII-6 received an IP injection of insulin (5 IU/kg/day) 
(Humulin; Eli Lilly and Company, Indianapolis, IN).14 
Groups GII-3 and GII-5 received propolis to ingest (in 
aqueous solution, 0.3 g/kg)15 and groups GII-4 and GII-6 
received a double dose of propolis to ingest (in aqueous 
solution, 0.6 g/kg),15 through an orogastric metallic needle.
At the end of the 6-week experimental period, the different 
treatment regimens were stopped, and food was stopped 
12 hours before sacrificing the rats. Animals were weighed and 
then anesthetized with an IP injection of ketamine (50 mg/kg) 
(Alfasan International BV , Woerden, the Netherlands).16 
Blood was collected directly from the abdominal aorta in two 
tubes by means of a vacutainer. One tube was heparinized for 
separation of plasma for hormonal studies, while the other 
tube was kept plain for fasting blood glucose (FBG) and 
separation of serum to determine the antioxidant activities. 
Plasma and serum was separated from blood samples by 
centrifugation at 3000 rpm for 10 minutes at 4°C, collected, 
and stored at −80°C until the time of analysis.15
Bone sampling
After drawing blood, the right femurs of all experimental rats 
were dissected out, cleansed of all soft tissue, washed with 
distilled water, and allowed to dry at room temperature for 
24 hours. Each dried femur was then weighed, put in an oven 
at 100°C for 24 hours, and then put in a furnace at 800°C for 
12 hours. The ash of each femur was collected separately, 
weighed, dissolved in 3 mL of 70% nitric oxide (Sigma-
Aldrich), and centrifuged; the supernatant was separated 
for the measurement of calcium (Ca), phosphorus (P), and 
magnesium (Mg) by the standard colorimetric method.17
Plasma insulin, glucagon, calcitonin,  
and parathyroid hormone
Plasma enzyme-linked immunosorbent assays (ELISAs) 
were used to estimate hormone levels. The Insulin ELISA 
kit (ALPCO Diagnostics, Salem, NH) used for   quantitative 
determination of plasma insulin concentration in rats is a one-
step sandwich enzyme immunoassay using two monoclonal 
antibodies.18 Pancreatic glucagon levels were determined 
by a highly specific ELISA kit (Wako Pure Chemical 
Industries, Ltd, Richmond, VA), based upon a competitive 
ELISA using a highly specific antibody to glucagon.19 The 
parathyroid   hormone (PTH) kit (ALPCO Diagnostics, Salem, 
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NH) is a two-site ELISA that quantitatively   determines the 
rat   bioactive intact PTH concentrations.18 The calcitonin 
  immunoassay kit (Phoenix Pharmaceuticals, Inc, Burlingame, 
CA) is a competitive enzyme immunoassay that detects 
calcitonin and its related peptides.20
Serum FBG levels and oxidative status
FBG concentrations were determined by a glucometer (Accu-
Chek Go, Roche Diagnostics GmbH, Indianapolis, IN).6 
The activity of superoxide dismutase (SOD)   (Cayman 
Chemical, Ann Arbor, MI) was determined through ELISA 
technique.21 Catalase (CAT) (Cayman Chemical) activity was 
measured using its peroxidative function.22 A thiobarbituric 
acid   reactive substances (TBARS) assay kit (Cayman 
Chemical) was used to measure the product of the reaction 
between malondialdehyde, a product of lipid peroxidation, 
and TBARS.23
Statistical analysis
All values reported are expressed as mean plus or minus 
standard error of the mean. Differences among means were 
analyzed for significance by analysis of variance using SPSS 
software (v 10; SPSS Inc, Chicago, IL). Groups were then 
compared by Fisher’s least significant difference tests, and 
P , 0.05 was considered statistically significant.
Results
Blood glucose, insulin, and glucagon
Significant differences in FBG, plasma insulin and glucagon, 
and insulin-glucagon (I/G) ratio were noted and are 
summarized in Table 1. Nontreated diabetic rats (coded NTD) 
had significantly higher mean FBG than all other groups. The 
mean blood glucose in all diabetic treated rats (including those 
treated with propolis only) was not significantly different from 
the negative control (coded C) group. With regard to plasma 
insulin, treated groups had significantly lower mean plasma 
insulin than the negative control group. Further, while the 
group treated with insulin only (insulin-treated diabetic rats, 
coded ITD) had plasma insulin comparable with the nontreated 
diabetic rats, the two groups treated with propolis plus insulin 
(propolis- and insulin-treated diabetic, coded PITD; double-
dose propolis- and insulin-treated diabetic, coded DPITD) had 
significantly higher plasma insulin than the nontreated diabetic 
rats. Concerning plasma glucagon, the nontreated diabetic rats 
had significantly higher plasma glucagon than all other groups. 
In addition, all groups treated with propolis, with the exception 
of propolis-treated diabetic (coded PTD) rats, had mean 
plasma glucagon comparable with that of the negative control 
group. Treatment with double-dose propolis plus insulin 
was associated with   significantly lower plasma glucagon 
than the two groups treated with either insulin or propolis 
alone. The results regarding I/G ratio were rather interesting. 
While the   negative control group had a significantly higher 
I/G ratio than all other groups, the two groups given mixed 
treatment with insulin plus propolis had a significantly higher 
I/G ratio than the positive control group and those groups 
treated with either insulin or propolis alone.
Antioxidant parameters
The mean serum TBARS levels (Figure 1), an indicator of 
lipid peroxidation, were found to be significantly higher 
in the nontreated diabetic rats than in the negative control 
group. Furthermore, the mean serum TBARS levels of all 
diabetic groups treated with propolis (with or without insu-
lin) were significantly lower than for the nontreated diabetic 
rats. Serum levels of the two antioxidant enzymes measured 
(CAT and SOD) were not shown to have significant differ-
ence among the studied groups.
Table 1 Fasting blood glucose (FBG), plasma insulin, plasma glucagon, and insulin-glucagon (i/G) ratio in the control and experimental 
groups of rats*
Group Treatment Code FBG (mg/dL) Insulin (ng/mL) Glucagon (ng/mL) I/G ratio
nondiabetic nontreated C 143.9 (6.8) 3.0 (0.25) 0.417 (0.029) 7.182 (0.09)
Diabetic nontreated nTD 509.3 (22.8)a 0.30 (0.04)a 1.2482 (0.16)a 0.207 (0.001)a
insulin iTD 182.0 (8)b 1.10 (0.26)a 0.949 (0.078)a,b 1.158 (0.03)a
Propolis PTD 153.7 (12.7)b 0.84 (0.3)a 0.929 (0.115)a,b 0.842 (0.03)a
Double propolis DPTD 127.6 (17.5)b 0.85 (0.4)a 0.755 (0.142)b 1.13 (0.02)a
insulin + propolis PiTD 156.2 (12.5)b 1.50 (0.04)a,b 0.669 (0.889)b 2.242 (0.05)a–e
insulin + double propolis DPiTD 127.1 (20.7)b 1.40 (0.06)a,b 0.587 (0.591)b–d 2.382 (0.05)a–e
Notes: *results are presented as mean (standard error of the mean). aSignificantly different from C; bsignificantly different NTD; csignificantly different ITD; dsignificantly 
different PTD; esignificantly different from DPTD using one-way analysis of variance at P , 0.05. There were ten rats in each group.
Abbreviations: C, nondiabetic; DPITD, double-dose propolis- and insulin-treated diabetic; DPTD, double-dose propolis-treated diabetic; ITD, insulin-treated diabetic; 
NTD, nontreated diabetic; PITD, propolis- and insulin-treated diabetic; PTD, propolis-treated diabetic.
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PTH, calcitonin, and bone mineralization
The results of plasma PTH, calcitonin, and FW/BW ratio 
are shown in Table 2. While, the nontreated diabetic rats 
had significantly higher mean plasma PTH than the negative 
control group, other groups did not. Moreover, mean serum 
PTH did not differ significantly between the treated diabetic 
subgroups. Mean plasma calcitonin was significantly higher 
in the nontreated diabetic group than in all other groups. 
In addition, no significant difference in plasma calcitonin 
among the diabetic treated groups was noted. As regards 
FW/BW ratio, no significant difference existed between 
the two control groups, negative and positive. However, 
the FW/BW ratio was significantly higher for all diabetic 
treated groups than for the positive control group. In 
addition, all groups treated with propolis (with or without 
insulin) had a higher FW/BW ratio than the negative 
control group. The concentration of ash in femur bones and 
the concentrations of Ca, P, and Mg provided interesting 
results, as summarized in Table 3. The bones of the negative 
control group and the two groups treated with insulin plus 
propolis had significantly higher ash contents than those of 
the positive control group. Treatment with either insulin or 
propolis alone did not significantly affect the concentration 
of ash in femur bones. The concentrations of Ca, P, and Mg 
in femur ash also showed significant differences among 
groups. The concentrations of these three minerals were 
significantly lower in the nontreated diabetic group than in 
all other groups. In addition, all groups treated with propolis 
(with or without insulin treatment, and with single- or 



































Figure 1 Mean serum levels of thiobarbituric acid reactive substances (TBArS) in the control and experimental groups of rats.
Notes: aSignificantly different from C; bsignificantly different from NTD using one-way analysis of variance at P , 0.05. There were ten rats in each group.
Abbreviations: C, nondiabetic; DPITD, double-dose propolis- and insulin-treated diabetic; DPTD, double-dose propolis-treated diabetic; ITD, insulin-treated diabetic; 
NTD, nontreated diabetic; PITD, propolis- and insulin-treated diabetic; PTD, propolis-treated diabetic.
Table 2 Plasma parathyroid hormone (PTH) and calcitonin levels and ratio of femur weight to body weight (FW/BW) in the control 
and experimental groups of rats*
Group Treatment Code PTH (pg/mL) Calcitonin (pg/mL) FW/BW ratio
nondiabetic nontreated C 44 (17.1) 1.5 (0.16) 0.02 (0.001)
Diabetic nontreated nTD 65.3 (16.5)a 3.2 (0.4)a 0.014 (0.004)
insulin iTD 54.2 (21.1) 1.6 (0.1)b 0.024 (0.003)b
Propolis PTD 53 ± 19.9 1.98 (0.1)b 0.025 (0.001)a,b
Double propolis DPTD 50.1 (19.5) 1.77 (0.3)b 0.028 (0.001)a,b
insulin + propolis PiTD 45.1 (20.5) 1.75 (0.4)b 0.028 (0.001)a,b
insulin + double propolis DPiD 44.3 (20) 1.69 (0.3)b 0.029 (0.003)a,b
Notes: *results are presented as mean (standard error of the mean). aSignificantly different from C; bsignificantly different from NTD using one-way analysis of variance at 
P , 0.05. There were ten rats in each group.
Abbreviations: C, nondiabetic; DPITD, double-dose propolis- and insulin-treated diabetic; DPTD, double-dose propolis-treated diabetic; ITD, insulin-treated diabetic; 
NTD, nontreated diabetic; PITD, propolis- and insulin-treated diabetic; PTD, propolis-treated diabetic.
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Mg concentrations than the diabetic group treated with 
insulin only. Furthermore, double-dose propolis treatment 
(with or without insulin treatment) was associated with a 
significantly higher ash P concentration than insulin-only 
treatment.
Discussion
This study on adult male albino rats confirms the earlier 
reports9 that propolis could almost control the hyperglyce-
mia in the STZ-induced diabetic rat model.24 The glycemic 
control achieved by propolis treatment could be due to the 
stimulation of glucose uptake by peripheral tissues, inhibition 
of its release in circulation,25 or reduced glucose absorption 
in the gut.10
However, the present study shows that propolis treatment 
in STZ-induced diabetic rats is associated with high plasma 
insulin and low glucagon levels. These findings suggest that 
decreased glucose output by the liver and increased glucose 
uptake by peripheral tissues were the probable mechanisms 
through which propolis achieved glycemic control.
However, the recovery of insulin secretion in diabetic 
rats is a partial restoration only, because insulin levels in all 
  diabetic rats treated with propolis were significantly lower 
than in the negative control group. The source of insulin 
in propolis-treated diabetic rats could be the β cells of the 
pancreas and therefore two possibilities are suggested: 
either propolis induces regeneration or it prevents further 
deterioration of β cells. Others have reported similar find-
ings on the ability of propolis to induce regenerative effects 
on β cells.10,11,15
As already noted, lipid peroxidation is the most potent 
oxidative defect that damages β cells in T1DM.26 All 
diabetic rats in the study treated with propolis alone or with 
insulin were observed showing significantly lowered lipid 
  peroxidation levels nearing normal control values, which 
  suggests that propolis prevents deterioration of β-cell 
  function. This finding confirms the earlier report that propolis 
causes   partial restoration of β-cell function.11 However, the 
authors could not confirm whether the glycemic control 
achieved by   propolis was also achieved by the inhibition of 
intestinal glucose absorption,10 as the rats were deprived of 
food for 12 hours before they were sacrificed.
However, propolis administration in the present study 
could not raise plasma insulin to the levels achieved 
by exogenous insulin administration, although it significantly 
lowered blood glucose to reach normal control values. This 
suggests that propolis administration causes inhibition 
of   glucose release from the liver and/or improvement of 
  peripheral tissue insulin sensitivity.
The study found that a decline in glucagon concentration 
in propolis-treated rats with elevation of the I/G ratio, again 
suggesting that decline in liver glucose output is an important 
mechanism in glycemic control by propolis. The study also 
found that a significant decline of glucagon concentrations 
in all propolis-treated diabetic rats compared with nontreated 
diabetic rats is due to insulin-induced inhibition of pancreatic 
α cells. This is because high insulin levels were found to be 
associated with significantly low glucagon levels in diabetic 
rats treated with both propolis and insulin. Additionally, 
compared with single-dose propolis-treated rats, double-dose 
propolis-treated rats showed low glucagon levels that were 
nearing negative control group levels, despite the insulin dose 
being the same for both groups (propolis-treated diabetic and 
double-dose propolis-treated diabetic [coded DPTD] rats). 
However, a direct inhibitory effect of propolis on α cells 
cannot be excluded and requires further investigation.
Evidence for a direct link between insulin and bone for-
mation in vivo is scant. Recent studies explain the potential 
Table 3 ratio of femur ash to femur weight (FA/FW) and calcium (Ca), phosphorous (P), and magnesium (Mg) concentrations in the 
control and experimental groups of rats*
Group Treatment Code FA/FW ratio Ca (%) P (%) Mg (%)
nondiabetic nontreated C 51.6 (3) 40.1 (0.95) 19 (0.63) 0.8 (0.01)
Diabetic nontreated nTD 41.9 (1.9)a 21.8 (2.55)a 13.8 (0.81)a 0.6 (0.03)a
insulin iTD 45.2 (1.3) 34.9 (0.88)a,b 16.2 (0.56)a,b 0.68 (0.02)a,b
Propolis PTD 43.7 (2.1) 39.5 (0.5)b,c 17.3 (0.54)a,b 0.76 (0.01)a–c
Double propolis DPTD 47.1 (2.9) 38.7 (0.8)b,c 18.4 (0.62)b,c 0.75 (0.01)a–c
insulin + propolis PiTD 48.4 (1)b 37.3 (0.89)a–d 17.5 (0.59)a,b 0.74 (0.01)a–c
insulin + double propolis DPiTD 50.5 (1.8)b,d 39.1 (1.06)b,c 18.2 (0.8)b,c 0.78 (0.01)a–c,e
Notes: *results are presented as mean (standard error of the mean). aSignificantly different from C; bsignificantly different from NTD; csignificantly different from ITD; 
dsignificantly different from PTD; esignificantly different from PITD using one-way analysis of variance at P , 0.05. There were ten rats in each group.
Abbreviations: C, nondiabetic; DPITD, double-dose propolis- and insulin-treated diabetic; DPTD, double-dose propolis-treated diabetic; ITD, insulin-treated diabetic; 
NTD, nontreated diabetic; PITD, propolis- and insulin-treated diabetic; PTD, propolis-treated diabetic.
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role of insulin as an anabolic agent in osteoblastogenesis.27 
Researchers have shown that bone regeneration is impaired 
by insulin deficiency but that it can be restored by insulin 
treatment, even with modrate hyperglycemia, indicating 
a primary role for insulin in bone formation.28 Hence, in 
diabetic states, bone formation rather than bone resorption 
is affected, leading to bone loss.29
The nontreated diabetic group showed serum insulin 
levels at about 10% of normal control values, exhibiting 
pronounced bone loss, reflected in a low ratio of femur ash to 
femur weight (FA/FW), as well as low bone concentrations 
of Ca, P, and Mg compared with the negative control group. 
This finding suggests that bone regeneration is impaired by 
insulin deficiency.
Despite the marked bone loss, FW/BW ratio showed 
a nonsignificant decline compared with the corresponding 
ratio from the negative control group. When compared with 
body weight in the nontreated diabetic group, masking of 
this bone loss may be secondary to the associated reduction 
in body weight.
Interestingly, Ca concentration in ash was reduced by 
almost 50% and that of P was reduced by about 30% only 
in nontreated diabetic rats, compared with the ones in the 
control group. Similar findings have been reported in insulin 
deficiency30 being associated with a decrease in both ash 
content and ratio of Ca to P in tibia ash. In another study 
in insulin deficiency,31 a significant decrease (.50%) of 
bone volume fraction in the tibia and femur of mice was 
demonstrated. Consistent loss of bone mass was detected by 
cytophotometry, due to a deficit in mineralized surface area 
in an untreated insulin-deficient state.32
In the present study, diabetic rats treated with propolis 
(with or without insulin) showed an increased FW/BW ratio 
compared with nontreated diabetic rats and the negative 
control group, reflecting an increased bone mass. On the 
other hand, only diabetic rats treated with propolis plus 
insulin showed a significant increase in the FA/FW ratio 
when compared with nontreated diabetic rats. However, 
the most striking feature was that all groups of diabetic 
rats treated with propolis (with or without insulin) showed 
Ca and Mg values significantly higher than nontreated 
diabetic rats and those diabetic rats treated with insulin 
alone, reflecting improvement of bone mineral content. 
Specifically, the double-dose propolis-treated groups 
(with or without insulin) showed Ca concentration levels 
in femur ash closer to those of the negative control group; 
Ca levels in nontreated diabetic rats were about 50% of the 
negative control.
The diabetic group also showed a significant rise of serum 
PTH and calcitonin levels as compared with the negative 
control group. PTH elevation is another factor for inducing 
bone loss, through both bone osteolysis and resorption.33 
This increase of serum PTH levels in diabetic rats could be 
due to an increase in Ca excretion accompanying g  lycosuria 
and a decreased Ca absorption secondary to deficiency 
of vitamin D.34 The mechanism behind the double rise in 
calcitonin concentration in diabetic rats and their return to 
normal levels by the different treatment regimen may pro-
vide a protective effect, ameliorating the bone loss effects of 
insulin deficiency and PTH elevation. However, this is not 
clear and needs further investigation.
In the present study, propolis showed remarkable effects 
on bone minerals, and therefore on bone mass, especially 
when administered with insulin to STZ-induced diabetic 
rats. Previous studies have reported propolis to have exerted 
an inhibitory action on osteoclasts, leading to attenuation of 
osteoclastogenesis, compared with insulin and its anabolic 
effects on bone osteoblasts.35 Another experimental study 
has reported that propolis inhibits late stages of osteoclast 
maturation, including fusion of osteoclast precursors to form 
giant cells.36 At the molecular level, an earlier study has 
documented that propolis has dual effects on osteoclasts: 
it inhibits osteoclastogenesis and it induces apoptosis.37 
It has also been reported that hyperglycemia contributes to 
diabetic bone complications through a variety of mechanisms 
including increasing the reactive oxygen species,37,38 polyol 
pathway activity,39 and protein kinase C activity.40 In addition, 
  hyperglycemia can induce an osmotic response in cells such 
as osteoblasts, leading to suppression of their activity.41
In this study, the authors observed that propolis 
administration through its glycemic control may play an 
important role in prevention of bone loss associated with 
the hyperglycemic state. In particular, the double propolis 
dose combined with insulin treatment could almost return 
bone mineralization to normal control levels. Therefore, the 
authors propose that when administered together, insulin, 
with its potent effect on bone formation, and propolis, with its 
inhibitory effect on bone resorption, can provide a promising 
therapy to protect against bone loss in T1DM.
Conclusion
In conclusion, experimental treatment of STZ-induced 
d  iabetic rats with propolis and insulin was found to 
  effectively control blood glucose level, improve function 
of the pancreatic islets, eliminate the oxidative stress, and 
protect bone from diabetic osteopathy. Clinical   application 
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of this combined therapy in humans requires further inves-
tigation and evaluation of its effectiveness and safety in 
T1DM patients.
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